280 related articles for article (PubMed ID: 33420124)
1. Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells.
Meng P; Zhang YF; Zhang W; Chen X; Xu T; Hu S; Liang X; Feng M; Yang X; Ho M
Sci Rep; 2021 Jan; 11(1):40. PubMed ID: 33420124
[TBL] [Abstract][Full Text] [Related]
2. A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.
Li N; Wei L; Liu X; Bai H; Ye Y; Li D; Li N; Baxa U; Wang Q; Lv L; Chen Y; Feng M; Lee B; Gao W; Ho M
Hepatology; 2019 Oct; 70(4):1231-1245. PubMed ID: 30963603
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling.
Capurro M; Martin T; Shi W; Filmus J
J Cell Sci; 2014 Apr; 127(Pt 7):1565-75. PubMed ID: 24496449
[TBL] [Abstract][Full Text] [Related]
4. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
Gao W; Kim H; Ho M
PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
[TBL] [Abstract][Full Text] [Related]
5. Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells.
Kwack MH; Choi BY; Sung YK
Mol Cells; 2006 Apr; 21(2):224-8. PubMed ID: 16682817
[TBL] [Abstract][Full Text] [Related]
6. Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma.
Akutsu N; Yamamoto H; Sasaki S; Taniguchi H; Arimura Y; Imai K; Shinomura Y
World J Gastroenterol; 2010 Jul; 16(28):3521-8. PubMed ID: 20653060
[TBL] [Abstract][Full Text] [Related]
7. The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling.
Magistri P; Leonard SY; Tang CM; Chan JC; Lee TE; Sicklick JK
J Surg Res; 2014 Apr; 187(2):377-85. PubMed ID: 24439425
[TBL] [Abstract][Full Text] [Related]
8. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
[TBL] [Abstract][Full Text] [Related]
12. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
13. A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma.
Maurel M; Jalvy S; Ladeiro Y; Combe C; Vachet L; Sagliocco F; Bioulac-Sage P; Pitard V; Jacquemin-Sablon H; Zucman-Rossi J; Laloo B; Grosset CF
Hepatology; 2013 Jan; 57(1):195-204. PubMed ID: 22865282
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
Wu Y; Liu H; Weng H; Zhang X; Li P; Fan CL; Li B; Dong PL; Li L; Dooley S; Ding HG
Int J Oncol; 2015 Mar; 46(3):1275-85. PubMed ID: 25572615
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
Filmus J; Capurro M
FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells.
Castillo LF; Tascón R; Lago Huvelle MR; Novack G; Llorens MC; Dos Santos AF; Shortrede J; Cabanillas AM; Bal de Kier Joffé E; Labriola L; Peters MG
Oncotarget; 2016 Sep; 7(37):60133-60154. PubMed ID: 27507057
[TBL] [Abstract][Full Text] [Related]
17. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K
Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.
Capurro MI; Xiang YY; Lobe C; Filmus J
Cancer Res; 2005 Jul; 65(14):6245-54. PubMed ID: 16024626
[TBL] [Abstract][Full Text] [Related]
19. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway.
Cheng W; Tseng CJ; Lin TT; Cheng I; Pan HW; Hsu HC; Lee YM
Carcinogenesis; 2008 Jul; 29(7):1319-26. PubMed ID: 18413366
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP.
Miao HL; Pan ZJ; Lei CJ; Wen JY; Li MY; Liu ZK; Qiu ZD; Lin MZ; Chen NP; Chen M
J Cell Biochem; 2013 Mar; 114(3):625-31. PubMed ID: 23060277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]